S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:ASMB

Assembly Biosciences Stock Forecast, Price & News

$6.05
+0.17 (+2.89 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.86
Now: $6.05
$6.10
50-Day Range
$5.94
MA: $6.11
$6.35
52-Week Range
$4.78
Now: $6.05
$27.84
Volume1.35 million shs
Average Volume776,201 shs
Market Capitalization$199.78 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs; and a collaboration and option agreement with Door Pharmaceuticals, LLC focused on the development of a hepatitis B virus core protein modulators. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.
Assembly Biosciences logo

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

301st out of 1,922 stocks

Pharmaceutical Preparations Industry

154th out of 771 stocks

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ASMB
CUSIP92282210
Phone833-509-4583
Employees140
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.96 million
Book Value$10.49 per share

Profitability

Net Income$-97,630,000.00

Miscellaneous

Market Cap$199.78 million
Next Earnings Date3/3/2021 (Estimated)
OptionableOptionable
$6.05
+0.17 (+2.89 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

How has Assembly Biosciences' stock price been impacted by COVID-19?

Assembly Biosciences' stock was trading at $15.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ASMB shares have decreased by 61.2% and is now trading at $6.05.
View which stocks have been most impacted by COVID-19
.

Is Assembly Biosciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Assembly Biosciences stock.
View analyst ratings for Assembly Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Assembly Biosciences?

Wall Street analysts have given Assembly Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Assembly Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

5 employees have rated Assembly Biosciences CEO John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among Assembly Biosciences' employees.

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Assembly Biosciences
.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.66. The biopharmaceutical company had revenue of $34.61 million for the quarter, compared to analyst estimates of $6.44 million. Assembly Biosciences had a negative trailing twelve-month return on equity of 18.75% and a negative net margin of 60.14%.
View Assembly Biosciences' earnings history
.

What price target have analysts set for ASMB?

5 brokers have issued 12-month price targets for Assembly Biosciences' shares. Their forecasts range from $10.00 to $55.00. On average, they expect Assembly Biosciences' stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 379.3% from the stock's current price.
View analysts' price targets for Assembly Biosciences
or view Wall Street analyst' top-rated stocks.

Who are some of Assembly Biosciences' key competitors?

What other stocks do shareholders of Assembly Biosciences own?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the following people:
  • Dr. John G. McHutchison A.O., M.D., FRACP, CEO, Pres & Director (Age 63, Pay $894.62k)
  • Mr. Thomas Joseph Russo C.F.A., CFA, CFO & Principal Accounting Officer (Age 49, Pay $209.37k)
  • Dr. Luisa M. Stamm M.D., Ph.D., Chief Medical Officer (Age 45, Pay $177.35k)
  • Dr. Uri A. Lopatin, Co-Founder and Clinical & Scientific Advisor (Age 49)
  • Dr. Adam Zlotnick, Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
  • Mr. Michael P. Samar, Sr. VP of Fin. & Bus. Operations
  • Ms. Lauren Glaser, Sr. VP of Investor Relations & Corp. Affairs
  • Mr. Jason A. Okazaki, Chief Legal & Bus. Officer and Corp. Sec. (Age 45)
  • Mr. Carl Henrik Enell M.Sc., Sr. VP of Corp. Devel.
  • Ms. Jennifer A. Troia MHROD, SPHR, SHRM-SCP, Sr. VP of HR and Organization Devel.

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (3.44%), Strs Ohio (0.11%) and Diversified Trust Co (0.07%). Company insiders that own Assembly Biosciences stock include Jacqueline Sybil Papkoff, Luisa M Stamm and Richard James Colonno.
View institutional ownership trends for Assembly Biosciences
.

Which major investors are buying Assembly Biosciences stock?

ASMB stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Strs Ohio, and Diversified Trust Co.
View insider buying and selling activity for Assembly Biosciences
or or view top insider-buying stocks.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $6.05.

How big of a company is Assembly Biosciences?

Assembly Biosciences has a market capitalization of $199.78 million and generates $15.96 million in revenue each year. The biopharmaceutical company earns $-97,630,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Assembly Biosciences employs 140 workers across the globe.

What is Assembly Biosciences' official website?

The official website for Assembly Biosciences is www.assemblybio.com.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.